Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Innovations in The Management of Diabetes: Next generation treatments and market dynamics

Published by: Business Insights

Published: Jun. 1, 2008 - 111 Pages


Table of Contents


Innovations in the Management of Diabetes
Executive Summary
Introduction
Currently marketed innovatives
Future drivers of growth and innovation
Key companies and pipelines
Future trends and implications
Chapter 1 Introduction
Summary
Introduction
Disease description
Type 1 diabetes
Type 2 diabetes
An increasing global health concern
Increasing patient population
Underdiagnosed and undertreated
Economic burden
Chapter 2 Currently marketed innovatives
Summary
Introduction
Current growth drivers
Insulins
Leading marketed innovatives within insulin
Exubera
Oral anti-diabetics (OADs)
Leading marketed innovatives in OADs
Other diabetic drugs
Leading marketed innovatives in other diabetic drugs
Chapter 3 Future drivers of growth and
innovation
Summary
Introduction
Unmet need
Key events in the global diabetes market
ACCORD trial halted 18 months early
Inhaled insulins fail to impact market
FDA considers stricter rules for diabetes drugs
Toward the prevention and further treatment of diabetes
Non-invasive forms of insulin via new drug delivery technologies
Inhaled insulins
Future potential of inhaled insulins
Oral insulins
Future potential of oral insulins
Insulin patches
Future potential of insulin patches
Emerging new drug classes: targeting underlying causes
Incretin mimetics: GLP-1 agonists and DDP-IV inhibitors
GLP-1 agonists in development
Novel GLP-1 agonists addressing unmet need
DDP-IV inhibitors in development
Novel DDP-IV inhibitors addressing unmet need
PPAR agonists
PPAR agonists in development
Novel PPAR agonists addressing unmet need
Sodium glucose co-transporter (SGLT) inhibitors
SGLT inhibitors in development
Cannabinoid-1 (CB1) receptor antagonists
CB-1 receptor antagonists in development
Glucokinase activators (GKA)
Glucokinase activators in development
Other novel drugs in development
Protein tyrosine phosphatase 1B (PT1B) inhibitors
Glycogen synthase kinase-3 (GSK-3) inhibitors
11-beta-hydroxysteroid dehydrogenase (11beta-HSD1) inhibitors
GPR119 agonists
Cell transplantation and innovative therapies
Chapter 4 Key companies and pipelines
Summary
Introduction
Leading competitive strategies
Lifecycle management
Diversification
Franchise development
New market entry
Leading players
Novo Nordisk
Currently marketed innovatives profile
R&D/innovatives profile
Takeda
Currently marketed innovatives profile
R&D/innovatives profile
Sanofi-Aventis
Currently marketed innovatives profile
R&D/innovatives profile
GSK
Currently marketed innovatives profile
R&D/innovatives profile
Lilly
Currently marketed innovatives profile
R&D/innovatives profile
Merck.
Currently marketed innovatives profile
R&D/innovatives profile
Chapter 5 Future trends and implications
Summary
Introduction
Future market growth
Competitive strategy and future potential
Chapter 6 Appendix
IMS data
Index
List of Figures
Figure 3.1: Unmet needs in diabetes, 2008
Figure 3.2: Innovative diabetes pipeline, 2007
Figure 3.3: Addressing unmet need of novel GLP-1 agonists versus insulin
Figure 3.4: Addressing unmet need of novel DDP-IV inhibitors versus TZDs
Figure 3.5: Addressing unmet need of novel PPAR agonists* versus TZDs
Figure 4.6: Competitive dynamics of the leading players in the diabetes market, 2007
Figure 5.7: Drivers and resistors of growth in the innovative diabetes market, 2007
Figure 5.8: Forecast sales growth for the global diabetes market, 2007-12
Figure 5.9: Outlook for leading pharmaceutical companies in the innovative diabetes market
List of Tables
Table 2.1: Breakdown of the global diabetes market by drug class, 2003-07
Table 4.2: Leading diabetes companies*, 2006-07
Table 4.3: Novo Nordisk’s currently marketed innovative diabetes profile, 2003-07
Table 4.4: Novo Nordisk’s diabetes R&D/innovatives profile
Table 4.5: Takeda’s currently marketed innovative diabetes profile, 2003-07
Table 4.6: Takeda’s diabetes R&D/innovatives profile
Table 4.7: Sanofi-Aventis’ currently marketed innovative diabetes profile, 2003-07
Table 4.8: Sanofi-Aventis’ diabetes R&D/innovatives profile
Table 4.9: GSK’s currently marketed innovative diabetes profile, 2003-07
Table 4.10: GSK’s diabetes R&D/innovatives profile
Table 4.11: Lilly’s currently marketed diabetes innovative diabetes, 2003-07
Table 4.12: Lilly’s diabetes R&D/innovatives profile
Table 4.13: Merck’s currently marketed innovative diabetes profile, 2003-07
Table 4.14: Merck’s diabetes R&D/innovatives profile


Abstract

‘Innovations in the Management of Diabetes: Next generation treatments and market dynamics’ is a new report published by Business Insights that analyzes the emerging drug classes, novel drug delivery technologies and future growth drivers of the diabetes market.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008